Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nancy Goudas

Nurse Practitioner Hickory, NC Nurse Practitioner

NPI 1396292017 CMS profile 10484644

2406 Century Pl Se, Hickory, NC 28602

Open in the dashboard

General payments

$9,233

429 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nancy Goudas of Hickory, NC is reported in the CMS Open Payments database as having received $9,233 across 429 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,658 119
2024 General $1,551 73
2023 General $2,018 87
2022 General $1,662 87
2021 General $1,344 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nancy Goudas
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Nancy Goudas were reported at $2,658. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Nancy Goudas Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,344 $135 $40–$426 $132
2022 $1,662 $152 $48–$470 $149
2023 $2,018 $166 $54–$529 $160
2024 $1,551 $173 $55–$556 $164
2025 $2,658 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $741 40 payments
  2. AstraZeneca Pharmaceuticals LP $586 31 payments
  3. Merck Sharp & Dohme Corporation $574 29 payments
  4. Incyte Corporation $570 21 payments
  5. Janssen Biotech, Inc. $471 24 payments
  6. AbbVie, Inc. $357 12 payments
  7. Astellas Pharma US Inc $350 11 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $332 12 payments
  9. Eisai Inc. $256 12 payments
  10. Seattle Genetics, Inc. $251 9 payments
  11. Other $4,744 228 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,444 420 payments
  2. Education $789 9 payments
Products named General payments · program years 2021–2025
  1. KEYTRUDA $553 28 payments
  2. JAKAFI $314 14 payments
  3. KISQALI $261 15 payments
  4. Lenvima $236 11 payments
  5. VENCLEXTA $234 5 payments
  6. LYNPARZA Oncology $210 11 payments
  7. IMBRUVICA $204 5 payments
  8. MONJUVI $200 10 payments
  9. FOTIVDA $200 8 payments
  10. LYNPARZA Oncology $199 10 payments
  11. Other $8,147 412 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

429

Median for Nurse Practitioner: 389

Drug cost

$200,381

Median for Nurse Practitioner: $21,885

Branded share of claims

24.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nubeqa Darolutamide Brand 11 $140,359
Eliquis Apixaban Brand 67 $54,228
Anastrozole Generic 88 $1,618
Tamoxifen Citrate Generic 65 $1,618
Valacyclovir Valacyclovir Hcl Brand 14 $697
Hydroxyurea Generic 33 $678
Ondansetron Hcl Generic 35 $370
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $265
Acyclovir Generic 25 $149
Prednisone Generic 33 $126

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 51 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
  • Novartis Pharmaceuticals Corporation $95
$95 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $79
$79 — —
FOTIVDA
  • Aveo Pharmaceuticals, Inc. $70
$70 — —
CABOMETYX
  • Exelixis Inc. $62
$62 — —
FRUZAQLA
  • Takeda Pharmaceuticals U.S.A., Inc. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 51 with Patron

Records

429 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record